EC Clinical and Medical Case Reports

Short Chain Fatty Acids (SCFA) are analyzed, metabolites that generate numerous beneficial processes, including the prevention of colon cancer. It is accepted that the first to discuss the topic were veterinarians and from them, we have learned countless issues about these metabolites. The various functions of fatty acids are evaluated, highlighting the transcendent role in maintaining health and the development of diseases.

Butyric acid is justified as the best fatty acid, as it is the most powerful inhibitor of histone deacetylases, preferred by colonocytes and improves liver disease.

The relationship of SCFA with neuroimmunoendocrinology and their role in the already famous microbiota-gut-brain axis, as well as other organs, are analyzed.

Intestinal dysbiosis and gastrointestinal diseases, as well as extra-gastrointestinal diseases, have their place, including the use SCFA as therapeutics, their adverse effects and the future of fatty acids.

 Keywords: Short Chain Fatty Acids (SCFA); Gut Microbiome (GM); Microbiota (M); Fecal Microbiota Transplant (FMT); Intestinal Microbiota Transplant (IMT)

1. Tan J., et al. “The role of short-chain fatty acids in health and disease”. Advances in Immunology 121 (2014): 91-119.
2. Lavoie S., et al. “Expression of free fatty acid receptor 2 by dendritic cells prevents their expression of interleukin 27 and is required for maintenance of mucosal barrier and immune response against colorectal tumors in mice”. Gastroenterology5 (2020): 1359-1372.
3. Jian Tan., et al. “Chapter Three - The role of short-chain fatty acids in health and disease”. Advances in Immunology 121 (2014): 91-119.
4. Sato Y., et al. “Sialyllactose enhances the short-chain fatty acid production and barrier function of gut epithelial cells via nonbifidogenic modification of the fecal microbiome in human adults”. Microorganisms2 (2024): 252.
5. Macfarlane S and Macfarlane GT. “Regulation of short-chain fatty acids production”. Proceedings of the Nutrition Society1 (2003): 67-72.
6. Silva YP., et al. “The role of short-chain fatty acids from gut microbiota in gut-brain communication”. Frontiers in Endocrinology (Lausanne) 11 (2020): 25.
7. Ratajczak W., et al. “Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs)”. Acta Biochimica Polonica 1 (2019): 1-12.
8. Bart van der Hee and Jerry M Wells. “Microbial regulation of host physiology by short-chain fatty acids”. Trends in Microbiology8 (2021): 700-712.
9. Yang X., et al. “Parkinson's disease is associated with impaired gut-blood barrier for short-chain fatty acids”. Movement Disorders8 (2022): 1634-1643.
10. Tyler J., et al. “Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cels”. Molecular and Cellular Neuroscience 105 (2020): 103493.
11. Kang P and Wang AZ. “Microbiota-gut-brain axis: the mediator of exercise and brain health”. Psychoradiology 4 (2024): kkae007.
12. Caetano-Silva ME., et al. “Inhibition of inflammatory microglia by dietary fiber and short-chain fatty acids”. Scientific Reports 13 (2023): 2819.
13. Huuskonen J., et al. “Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids”. British Journal of Pharmacology5 (2004): 874-880.
14. Yang Y., et al. “Microglial depletion and abnormalities in gut microbiota composition and short-chain fatty acids in mice after repeated administration of colony stimulating factor 1 receptor inhibitor PLX5622”. European Archives of Psychiatry and Clinical Neuroscience 3 (2022): 483-495.
15. Chayon Goswami., et al. “Short-chain fatty acids suppress food intake by activating vagal afferent neurons”. The Journal of Nutritional Biochemistry 57 (2018): 130-135.
16. Aho VTE., et al. “Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease”. Molecular Neurodegeneration 1 (2021): 6.
17. Xiong RG., et al. “Health benefits and side effects of short-chain fatty acids”. Foods 18 (2022): 2863.
18. Qin Zeng., et al. “Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis”. Neurochemistry International 129 (2019): 104468.
19. Kraft AK and Berger K. “Quality of care for patients with multiple sclerosis-a review of existing quality indicators”. Frontiers in Neurology 12 (2021): 708723.
20. De la Cuesta-Zuluaga J., et al. “Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors”. Nutrients1 (2019): 51.
21. Bojović K., et al. “Gut microbiota dysbiosis associated with altered production of short chain fatty acids in children with neurodevelopment disorders”. Frontiers in Cellular and Infection Microbiology 10 (2020): 223.
22. Rau M., et al. “Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease”. United European Gastroenterology Journal10 (2018): 1496-1507.
23. Talley NA., et al. “Short-chain fatty acids in the treatment of radiation proctitis”. Diseases of the Colon and Rectum 9 (1997): 1046-1050.
24. Mortensen PB and Clausen MR. “Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease”. Scandinavian Journal of Gastroenterology 216 (1996): 132-148.
25. Sanna S., et al. “Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases”. Nature Genetics 51 (2019): 600-605.
26. Yao Y., et al. “The role of short-chain fatty acids in immunity, inflammation and metabolism”. Critical Reviews in Food Science and Nutrition1 (2020): 1-12.
27. Hu J., et al. “Short-chain fatty acids in control of energy metabolism”. Critical Reviews in Food Science and Nutrition8 (2017): 1243-1249.
28. Sajdel-Sulkowska EM. “Neuropsychiatric ramifications of covid-19: short-chain fatty acid deficiency and disturbance of microbiota-gut-brain axis signaling”. BioMed Research International (2021): 7880448.
29. RJF Felizardo., et al. “The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids”. Pharmacological Research 141 (2019): 366-377.
30. Ashkan Rasouli-Saravani., et al. “Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases”. Biomedicine and Pharmacotherapy 162 (2023): 114620.
31. Faezeh Golpour., et al. “Short chain fatty acids, a possible treatment option for autoimmune diseases”. Biomedicine and Pharmacotherapy 163 (2023): 114763.
32. Mizuno M., et al. “The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models”. PLOS ONE2 (2017): e0173032.
33. Luu M and Visekruna A. “Short-chain fatty acids: Bacterial messengers modulating the immunometabolism of T cells”. European Journal Immunology6 (2019): 842-848.
34. Igudesman D., et al. “The intestinal microbiota and short-chain fatty acids in association with advanced metrics of glycemia and adiposity among young adults with type 1 diabetes and overweight or obesity”. Current Developments in Nutrition 10 (2022): nzac107.
35. Zhang S., et al. “Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease”. Obesity Review11 (2021): e13316.
36. Cleveland Clinic. Dysbiosis: Wath it is, symptoms, causes, treatment & diet.
37. Brown K., et al. “Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease”. Nutrients 8 (2012): 1095-1119.
38. Khatri M. “What to know about short chain fatty acids in food”. WebMD (2023).
39. Chen C., et al. “The effect of lipid metabolism regulator anthocyanins from Aronia melanocarpa on 3T3-L1 preadipocytes and C57BL/6 mice via activating AMPK signaling and gut microbiota”. Journal of Food and Function14 (2021): 6254-6270.
40. Tumani MF., et al. “The role of intestinal microbiota in the development of non-alcoholic fatty liver disease”. Revista Médica de Chile 4 (2021).
41. Facchin S., et al. “Short-chain fatty acids and human health: from metabolic pathways to current therapeutic implications”. Life 5 (2024): 559.
42. Duan WX., et al. “Relationship between short-chain fatty acids and Parkinson’s disease: a review from pathology to clinic”. Neuroscience Bulletin 4 (2024): 500-516.
43. Chowdhury GMI., et al. “Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenase-deficient mice: evidence for glial dysfunction and reduced glutamate/glutamine cycling”. Journal of Neurochemistry5 (2007): 2077-2091.
44. Singh V., et al. “Butyrate producers, "The Sentinel of Gut": Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics”. Frontiers in Microbiology 13 (2023): 1103836.
45. Hashempour-Baltork F., et al. “The effect of probiotics on various diseases and their therapeutic role: an update review”. Journal of Pure and Applied Microbiology 3 (2021): 1042-1058.
46. Nagpal R., et al. “Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome”. Scientific Reports 1 (2018): 12649.
47. Pierre JF., et al. “Journal of Nutritional Biochemistry Special Issue: nutritional modulation of the gut microbiome in gastrointestinal and metabolic disease”. Journal of Nutritional Biochemistry 66 (2019): 110-112.
48. Su SH., et al. “Fecal microbiota transplantation and short-chain fatty acids protected against cognitive dysfunction in a rat model of chronic cerebral hypoperfusion”. CNS Neuroscience and Therapeutics1.1 (2023): 98-114.
49. Faezeh Golpour., et al. “Short chain fatty acids, a possible treatment option for autoimmune diseases”. Biomedicine and Pharmacotherapy 163 (2023): 114763.